Perspective Therapeutics updates corporate presentation with estimated cash balance and pipeline milestones

Perspective Therapeutics, Inc.

Estimated cash, cash equivalents and short-term investments as of Dec 31, 2025 disclosed (amount not specified in filing).
Phase 1/2 data expected across all three clinical programs during 2026.
VMT-α-NET shows durable disease control and best-in-class safety profile in neuroendocrine tumors.
VMT01 exhibits preliminary anti-tumor activity at lower doses in melanoma.
PSV359 targeting FAP-α for solid tumors is ongoing in Phase 1/2a trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.